oasis-1 oral semaglutide 50 mg obesity nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Obesity: once-daily oral GLP-1 orforglipron

Non-Diabetic PAD Patients on GLP-1RAs Show Reduced Risk of Serious Cardiovascular Outcomes Compared to Those Without GLP-1RAs PAD is a condition where the peripheral arteries that carry blood away from the heart to other parts of the body become narrowed or blocked, reducing blood flow to the limbs, often in the legs

What is the biggest side effect of Ozempic

Rev ChilPediatr 89:525529 Boafor TK, Olayemi E, Galadanci N et al (2016) Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis

What has been less clear is the mechanism by which small-molecule GLP-1s work

10.1210/en.2015-1551 345

If someone is over 60, it is best to stay toward the higher end of the protein range, even with a moderate activity level